Breaking News

Envigo, Biocytogen Enter Mouse Model Research Pact

B-NDG Triple Immunodeficient model is used in research and drug discovery in oncology, immuno-oncology, infectious disease, and stem cell biology.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Envigo RMS Holding Corp. has entered a collaboration with Biocytogen, a global biotech company leveraging innovative technologies, to support research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the U.S., Europe, and certain Asia-Pacific regions.   The triple immunodeficient B-NDG mouse model was independently designed and produced by Biocytogen. Lacking mature T cells, B cells or functional NK cells, and displaying cytokine signali...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters